Trial Information
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
